在血压控制不佳的高血压患者中加用齐莱贝西兰治疗:KARDIA-2随机临床试验
这项2期、随机、前瞻性、双盲试验在8个国家150个中心纳入接受吲达帕胺、氨氯地平或奥美沙坦治疗后血压仍未控制的成人高血压患者,比较加用单次皮下注射齐莱贝西兰600 mg与安慰剂的疗效。3个月时,齐莱贝西兰组24小时平均动态收缩压较基线的下降幅度在三个队列中均显著大于安慰剂组,严重不良事件发生率低。
要点
- 在吲达帕胺基础上加用齐莱贝西兰,3个月24小时平均动态收缩压较安慰剂多降低12.1 mm Hg。
- 在氨氯地平基础上加用齐莱贝西兰,3个月24小时平均动态收缩压较安慰剂多降低9.7 mm Hg。
- 在奥美沙坦基础上加用齐莱贝西兰,3个月24小时平均动态收缩压较安慰剂多降低4.5 mm Hg。
核心结论
- 在接受吲达帕胺、氨氯地平或奥美沙坦治疗后血压仍未控制的患者中,加用单次剂量齐莱贝西兰在3个月时较安慰剂显著降低收缩压,严重不良事件发生率低。
研究设计与样本
- 这项2期、随机、前瞻性、双盲试验于2022年1月至2023年6月在8个国家的150个中心纳入血压未控制的成人高血压患者。
- 进入开放标签导入期的1491例患者中,663例被随机分配接受齐莱贝西兰(n=332)或安慰剂(n=331)。
- 导入期治疗为吲达帕胺2.5 mg、氨氯地平5 mg或奥美沙坦40 mg每日一次,至少4周,随机比为4:7:10。
- 导入期后,24小时平均动态收缩压为130 mm Hg至160 mm Hg且依从的患者按1:1随机接受单次皮下注射齐莱贝西兰600 mg或匹配安慰剂。
- 末次随访日期为2023年12月11日,分析于2024年3月1日进行。
主要发现
- 吲达帕胺队列中,齐莱贝西兰与安慰剂相比,3个月时24小时平均动态收缩压较基线变化的最小二乘均值差为-12.1 mm Hg(95% CI,-16.5至-7.6;P < .001)。
- 氨氯地平队列中,齐莱贝西兰与安慰剂相比,3个月时24小时平均动态收缩压较基线变化的最小二乘均值差为-9.7 mm Hg(95% CI,-12.9至-6.6;P < .001)。
- 奥美沙坦队列中,齐莱贝西兰与安慰剂相比,3个月时24小时平均动态收缩压较基线变化的最小二乘均值差为-4.5 mm Hg(95% CI,-8.2至-0.8;P = .02)。
- 跨队列比较,齐莱贝西兰组较安慰剂组更多患者发生高钾血症(18例[5.5%] vs 6例[1.8%])、低血压(14例[4.3%] vs 7例[2.1%])和急性肾衰竭(16例[4.9%] vs 5例[1.5%])事件,但多数发作轻微且无需医疗干预即缓解。
关键数值与推荐
- 各队列主要终点为齐莱贝西兰与安慰剂相比,3个月时24小时平均动态收缩压较基线变化的差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In prior monotherapy studies of patients with hypertension, single subcutaneous doses of zilebesiran, an investigational RNA interference therapeutic, reduced serum angiotensinogen levels and systolic blood pressure (SBP) at 3 and 6 months. OBJECTIVE: To evaluate the efficacy and safety of zilebesiran vs placebo when added to a standard antihypertensive medication. DESIGN, SETTING, AND PARTICIPANTS: This phase 2, randomized, prospective, double-blinded trial enrolled adults with uncontrolled hypertension from 150 sites across 8 countries between January 2022 and June 2023. The final follow-up date was December 11, 2023, and analyses were conducted on March 1, 2024. INTERVENTIONS: Eligible patients were initially randomized in cohorts to receive open-label run-in treatment for at least 4 weeks with indapamide 2.5 mg, amlodipine 5 mg, or olmesartan 40 mg (4:7:10 randomization), each administered once daily. Within cohorts, adherent patients with 24-hour mean ambulatory SBP of 130 mm Hg to 160 mm Hg were subsequently randomized (1:1) to additional blinded treatment to receive single subcutaneous doses of zilebesiran 600 mg or matching placebo. MAIN OUTCOMES AND MEASURES: The primary end point in each cohort was the difference between zilebesiran and placebo in change from baseline in 24-hour mean ambulatory SBP at 3 months. RESULTS: Of 1491 patients entering the run-in phase, 663 (130 receiving indapamide, 240 receiving amlodipine, and 293 receiving olmesartan) were randomized to receive zilebesiran (n = 332) or placebo (n = 331). The least-squares mean difference between zilebesiran and placebo in change from baseline to 3 months in 24-hour mean ambulatory SBP was -12.1 mm Hg (95% CI, -16.5 to -7.6; P < .001) for indapamide, -9.7 mm Hg (95% CI, -12.9 to -6.6; P < .001) for amlodipine, and -4.5 mm Hg (95% CI, -8.2 to -0.8; P = .02) for olmesartan. Across cohorts, more patients who received zilebesiran than placebo experienced hyperkalemia (18 [5.5%] vs 6 [1.8%]), hypotension (14 [4.3%] vs 7 [2.1%]), and acute kidney failure (16 [4.9%] vs 5 [1.5%]) events, but most episodes were mild and resolved without medical intervention. CONCLUSIONS AND RELEVANCE: In patients with uncontrolled hypertension despite treatment with indapamide, amlodipine, or olmesartan, the addition of single-dose zilebesiran resulted in significant SBP reductions compared with placebo at 3 months, with low rates of serious adverse events. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05103332.
引用
- Desai AS, Karns AD, Badariene J, et al. Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension: The KARDIA-2 Randomized Clinical Trial. JAMA. 2025. PMID: 40434761. doi:10.1001/jama.2025.6681
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。